Radiation cystitis is a serious long-term complication of pelvic radiation that can cause significant bleeding, repeated hospitalizations, transfusions, and a substantial decline in quality of life. Current treatment options often provide only temporary relief or carry meaningful risks.
Rather than simply managing symptoms, HBOT treats the underlying radiation damage by promoting new blood vessel growth, improving tissue oxygenation, reducing fibrosis, and supporting tissue repair.
A growing body of evidence demonstrates that HBOT significantly improves symptoms and quality of life for patients with radiation cystitis, particularly in patients who begin HBOT soon after symptom onset.
Clinical benefits have been shown to persist for years after treatment, while claims-based research suggests improved outcomes and lower total medical costs compared with standard care alone.
